publication date: Jul. 1, 2016

Multiple Myeloma Kyprolis, Lenalidomide and Dexamethasone Combination Improves PFS, OS in Phase III


A secondary analysis of the phase III ASPIRE trial that showed Kyprolis (carfilzomib) for Injection, in combination with lenalidomide and dexamethasone, improved progression-free survival and overall response rate, compared to lenalidomide and dexamethasone alone, in patients with relapsed multiple myeloma with early disease progression after initial therapy or transplant.

The analysis showed that patients relapsing within one year of initial therapy treated with Kyprolis (n=87) experienced a median PFS of 24.1 months versus 12.5 months in the control arm (n=72) (HR=0.75; 95 percent CI: 0.50-1.13).

ORR in the Kyprolis arm was 79.3 percent compared to 61.1 percent. Patients relapsing early after first prior transplant treated with the Kyprolis combination (n=48) experienced a median PFS of 17.3 months versus 11.1 months in patients receiving lenalidomide and dexamethasone alone (n=49) (HR=0.87; 95 percent CI: 0.54-1.41). ORR in the experimental arm was 83.3 percent versus 61.2 percent in the control arm.

Grade 3 adverse events that occurred at least five percent more frequently in the Kyprolis arm, in either subgroup, were hypokalemia, neutropenia, febrile neutropenia, hypophosphatemia and respiratory tract infection. The study results were presented at the annual meeting of the American Society of Clinical Oncology.

“A goal in treating relapsed multiple myeloma is to get patients into remission, and keep them … Continue reading CCL June 2016 – Multiple Myeloma Kyprolis, Lenalidomide and Dexamethasone Combination Improves PFS, OS in Phase III

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.